[Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B].
Ishikawa
Tetsuya
T
Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine.
Kakumu
Shinichi
S
D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000097:blood; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000276:immunology / Q000628:therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens; D019259:Lamivudine; D000410:Alanine Transaminase